Synthes grows but feels the heat from rivals
This article was originally published in Clinica
Swiss orthopaedic company Synthes saw a good start to 2007, with all product lines showing continued growth in the first quarter of the year. Worldwide sales for the period jumped 14.2% from last year's level to $658m.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.